| Study Period | 2019 - 2030 |
| Market Size (2025) | USD 3.88 Billion |
| Market Size (2030) | USD 6.22 Billion |
| CAGR (2025 - 2030) | 9.90 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
In-Silico Drug Discovery Market Analysis
The In-Silico Drug Discovery Market size is estimated at USD 3.88 billion in 2025, and is expected to reach USD 6.22 billion by 2030, at a CAGR of 9.9% during the forecast period (2025-2030).
In-silico drug discovery refers to the use of computer-based simulations and computational techniques to identify, design, and optimize potential drug candidates. This approach leverages technologies such as molecular modeling, virtual screening, and artificial intelligence (AI) to predict how drug molecules will interact with biological targets, significantly reducing the time and cost associated with traditional drug discovery processes. The cost-effectiveness of in-silico drug discovery is expected to boost the adoption of these methods, thereby driving market growth.
For instance, a research article titled 'In Silico for Drug Discovery,' published in January 2023, states that with technological advancements, ISCTs have become a crucial part of drug development, evolving into a more economical and effective option than animal testing. The above source also stated that enormous amounts of information about earlier drug research, including the causes of success or failure, can be accessed through computers.
Similarly, another research article, 'Intelligent Pharmacy,' published in February 2024, mentioned that aspects of drug discovery and development, such as virtual ligand screening and profiling, target and lead finding, and compound library creation, are effectively simulated by computational approaches. Thus, the use of in-silico research in drug development is growing. Such factors are expected to propel the demand for in-silico drug discovery market.
Furthermore, market players are engaged in marketing tactics such as mergers and acquisitions and product launches. For instance, in November 2023, Certara, Inc. unveiled its Simcyp biopharmaceutics software, tailored for biopharmaceutic, formulation, and CMC scientists. This software streamlines the formulation of both novel and generic small molecule medicines, ensuring efficiency and cost-effectiveness. Such launches are expected to boost the market's growth in the upcoming years.
As a result of the reasons outlined, the market is anticipated to grow throughout the analysis period. However, since human subjects are not involved, the results are based on an approximation that can restrain market growth in silico clinical drug discovery.
In-Silico Drug Discovery Market Trends
Software Expected to Register Healthy Growth Over the Forecast Period
Software segment in the in silico drug discovery market is driven by its efficiency, cost-effectiveness, precision, ability to explore diverse chemical space, integration of big data and AI, support for collaboration, emphasis on regulatory compliance and safety, continuous pharmaceutical research and development funding, and continuous evolution of technology.
In silico drug discovery software reduces the need for extensive laboratory experiments, leading to cost savings and faster drug development timelines, which is likely to drive the segment growth. For instance, a research article titled "Why Artificial Intelligence Could Speed Drug Discovery," published by Morgan Stanley in September 2023, highlighted that AI software in silico can reduce the cost of preclinical drug development by 20-40% and accelerate the design and validation of drug candidates by as much as 15 times. Such highlights are expected to boost the segmental's growth within the market over the study period.
Moreover, market players are engaged in marketing tactics such as product launches drive segment growth. For instance, in December 2023, Merck has unveiled its AIDDISON drug discovery software. This pioneering software-as-a-service platform seamlessly connects virtual molecule design with real-world manufacturability, thanks to its integration with the SynthiaTM retrosynthesis software application programming interface.
Thus, combining the cost-saving benefits and accelerated timelines offered by in-silico drug discovery software with ongoing technological innovations and strategic initiatives such as product launches and collaborations, the in-silico drug discovery software market is poised for significant growth.
Understand The Key Trends Shaping This Market
Download PDF
North America is Expected to Dominate the In-Silico Drug Discovery Market during the Forecast Period
The North America market is anticipated to grow during the forecast period due to the increasing burden of chronic diseases, rising demand for pharmaceutical products, the emergence of companies focusing on in-silico drug development and clinical trials, increasing R&D activities, and the presence of manufacturers.
The North American market has witnessed significant advancements in in-silico drug discovery due to increasing research and development activities and an improved understanding of the benefits of in-silico trials. For instance, in June 2024, Washington State University published news highlighted that researchers from Washington State University used a generative AI model to predict the interaction between drug molecules and proteins in the cell membrane. They found that their novel method cut down significantly on the time it takes to make these predictions. Such factors propel the region's growth within the market over the study period.
Furthermore, workshops and events focused on in-silico drug discovery play a pivotal role in advancing the adoption of computational methodologies within the pharmaceutical sector. For instance, the In-silico Drug Discovery Workshop, part of the AGM Event, was scheduled virtually in October 2024. Therefore, events like this contribute significantly to the growth of the in-silico drug discovery market in the United States, driving innovation, fostering industry partnerships, and accelerating the adoption of AI-driven and computational techniques in drug development, thereby driving the market's growth.
Additionally, key players' strategic activities, such as investment and collaboration, are all factors that have contributed to the growth of the in silico drug development market. For instance, in June 2023, Insilico plans to investigate its AI-generated drug INS018-055 in patients with Idiopathic Pulmonary Fibrosis based in the United States.
Similarly, in June 2022, In silico Medicine raised USD 60 million in Series D financing from a syndicate of global investors with expertise in investing in the biopharmaceutical and life sciences sectors. In silico also launched a new state-of-the-art robotics lab and fully robotic biological data factor.
Therefore, the North American market is expected to witness significant growth over the forecast period due to the abovementioned factors.
Get Analysis on Important Geographic Markets
Download PDF
In-Silico Drug Discovery Industry Overview
The in-silico drug discovery market is moderately competitive, with many players in the market providing their services and software. Each entity contributes to this competitiveness through unique innovations, regional launches, partnerships with diverse organizations, and promotions across various leading platforms. Some of the key players operating in the market are Nova, Insilico Medicine Inc., Clarivate, Dassault Systèmes SE, and InSilicoTrials Technologies, among others.
In-Silico Drug Discovery Market Leaders
-
Nova
-
Insilico Medicine Inc.
-
Clarivate
-
Dassault Systèmes SE
-
InSilicoTrials Technologies
- *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competiters?
Download PDF
In-Silico Drug Discovery Market News
- January 2024: United States Food and Drug Administration in collaboration with Dassault Systèmes introduced The in-silico clinical trials playbook. The playbook highlights the program's use of virtual human modeling and generative AI to develop in-silico clinical trials for both medical devices and pharmaceuticals.
- February 2022: IonsGate Preclinical Services has partnered with InSilicoTrials to transform the landscape of drug development. InSilicoTrials is set to provide advanced modeling and simulation technology to digitize IonsGate's drug development processes. This collaboration aims to not only cut down the costs and time associated with preclinical testing but also enhance the safety profile of new compounds.
In-Silico Drug Discovery Industry Segmentation
As per the scope of the report, in-silico drug discovery refers to the use of computer-based techniques and simulations to identify, design, and evaluate potential drug candidates.
The in-silico drug discovery market is segmented by product, therapeutic area, and end user. In terms of products, the market is segmented as software and services. In terms of therapeutic areas, the market is segmented as oncology, infectious disease, cardiology, neurology, diabetes, and other therapeutic areas. By end user, the market is segmented as pharmaceutical and biotechnology companies, contract research, organizations, academic institutes and research centers. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (USD) for the above segments.
| By Product | Software | ||
| Services | |||
| By Therapeutic Area | Oncology | ||
| Infectious Disease | |||
| Cardiology | |||
| Neurology | |||
| Diabetes | |||
| Other Therapeutic Areas | |||
| By End User | Pharmaceutical and Biotechnology Companies | ||
| Contract Research Organization | |||
| Academic Institutes and Research Centers | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
Need A Different Region or Segment?
Customize Now
In-Silico Drug Discovery Market Research FAQs
How big is the In-Silico Drug Discovery Market?
The In-Silico Drug Discovery Market size is expected to reach USD 3.88 billion in 2025 and grow at a CAGR of 9.90% to reach USD 6.22 billion by 2030.
What is the current In-Silico Drug Discovery Market size?
In 2025, the In-Silico Drug Discovery Market size is expected to reach USD 3.88 billion.
Who are the key players in In-Silico Drug Discovery Market?
Nova, Insilico Medicine Inc., Clarivate, Dassault Systèmes SE and InSilicoTrials Technologies are the major companies operating in the In-Silico Drug Discovery Market.
Which is the fastest growing region in In-Silico Drug Discovery Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in In-Silico Drug Discovery Market?
In 2025, the North America accounts for the largest market share in In-Silico Drug Discovery Market.
What years does this In-Silico Drug Discovery Market cover, and what was the market size in 2024?
In 2024, the In-Silico Drug Discovery Market size was estimated at USD 3.50 billion. The report covers the In-Silico Drug Discovery Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the In-Silico Drug Discovery Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
In-Silico Drug Discovery Industry Report
Statistics for the 2025 In-Silico Drug Discovery market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. In-Silico Drug Discovery analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
